Dr. Berg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215
Summary
- Dr. Stephanie Berg is a Boston-based Oncologist with a subspecialty in Genitourinary Oncology. She completed her residency in Internal Medicine at the University of Illinois College of Medicine at Chicago and a fellowship in Hematology and Medical Oncology at Loyola University Medical Center. Currently, she is associated with the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Previously, she served as an Assistant Professor at Loyola University Medical Center and a Hematologist/Oncologist at Edward Hines Jr. Veterans Affairs Hospital. Dr. Berg has experience treating conditions like amyloidosis, renal cell carcinoma, urothelial carcinoma, and prostate cancer, among others. In addition, she has written several publications and been cited twice. She has also been part of clinical trials, researching topics like the use of Pelabresib in Myelofibrosis and the effectiveness of Immunotherapy drugs.
Education & Training
Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
University of Illinois College of Medicine at ChicagoChief Residency, Internal Medicine, 2014 - 2015- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2011 - 2014
Lake Erie College of Osteopathic Medicine Bradenton CampusClass of 2011
University of MiamiBS, Biology, 2001 - 2005
Certifications & Licensure
FL State License 2024 - Present
IL State License 2013 - 2026
NH State License 2024 - 2026
CT State License 2024 - 2025
MA State License 2022 - 2025
ME State License 2024 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- ACLS ACLS
Clinical Trials
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Start of enrollment: 2019 Jun 07
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Start of enrollment: 2019 May 13
- Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects Start of enrollment: 2020 Jan 31
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsPathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.Justine Panian, Ava Saidian, Kevin Hakimi, Archana Ajmera, William J Anderson
The Oncologist. 2024-10-03 - 4 citationsAdjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.Andrea B Apolo, Karla V Ballman, Guru Sonpavde, Stephanie Berg, William Y Kim
The New England Journal of Medicine. 2024-09-15 - 2 citationsSafety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.Kylie Fletcher, Alessio Cortellini, Teja Ganta, Roma Kankaria, Haocan Song
Cancer Letters. 2024-08-01
Press Mentions
Study Shows Structural Racism Can Result in Poorer Leukemia OutcomesMarch 7th, 2022- DCVAC/PCa Use Alongside Chemotherapy Shows No Additional mCRPC Survival BenefitFebruary 28th, 2022
- Active Cellular Immunotherapy Disappoints in Metastatic Prostate CancerFebruary 10th, 2022
Committees
- Executives Officer, Experimental Therapeutics and Rare Tumors, Alliance for Clinical Trials in Oncology 2021 - Present
Professional Memberships
- Member
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
